Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × nimotuzumab × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Gastrointestinal 1

Conditions

Esophageal Squamous Cell Carcinoma 11 Esophageal Neoplasms 11 Pancreatic Neoplasms 8 Stomach Neoplasms 3 Pancreatic cancer, adult 2 Colorectal Neoplasms 2 Squamous Cell Carcinoma of Anal Canal 1 Resectable Pancreatic Cancer 1 Pancreatic Cancer Resectable 1 Neoplasm Metastasis 1 Esophageal 1 Advanced Pancreatic Cancer 1 Advanced Esophageal 1 Advanced Colorectal Cancer 1 Adenocarcinoma 1

Interventions

Oxaliplatin 28 Fluorouracil 26 Gemcitabine 25 Capecitabine 21 Leucovorin 18 pembrolizumab 15 130-nm albumin-bound paclitaxel 12 Irinotecan 11 Cisplatin 10 Bevacizumab 10 Albumin-Bound Paclitaxel 10 Paclitaxel 9 Radiotherapy 8 Ramucirumab 7 Nivolumab 7 Docetaxel 7 trastuzumab deruxtecan 6 Cyclophosphamide 6 durvalumab 4 Taxes 4 Metformin 4 zolbetuximab 3 folfirinox 3 cemiplimab 3 XELOX 3 Trastuzumab 3 Surgical Procedures, Operative 3 Sorafenib 3 Ipilimumab 3 Drug Therapy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01249352 2025-03-31

NICE

Eurofarma Laboratorios S.A.

Phase 2/3 Completed

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡